- Oral presentation
- Open Access
The role of prednisolone in acute urticaria management
Clinical and Translational Allergy volume 5, Article number: O8 (2015)
To evaluate the efficacy of a 5 day short course of oral prednisolone when added with levocetirizine for management of acute urticaria.
Materials and methods
Prospective, randomized clinical trial was carried out in a teaching hospital.
All patients were asked to evaluate the severity of pruritus on urticarial activity score (UAS).
Patients were then given oral prednisolone 30 mg for 5 days and tablet levocetirizine 5 mg twice daily for 6 weeks and only levocetirizine tablet 5 mg twice daily for 6 weeks. Patients’ conditions were reassessed clinically with UAS calculated again 2 days later and again 5 days later.
49 patients were enrolled; 24 patients received prednisolone with Levocetirizine and 25 received only Levocetirizine. The two groups had similar UAS at enrollment (prednisolone, 4.6 ; levocetirizine ,4.4 ) , but at 2- and 5- day follow-up the prednisolone group had significantly lower UAS (1.4 and 0.2 versus 3.8 and 2.4 respectively) and greater clinical improvement in rash. Response did not correlate with age, sex, or identification of an allergen. No adverse effects were noted in levocetirizine group. In Prednisolone group two patients complained of gastritis.
At the end of 6 weeks, 3 patients from the steroid group and 8 patients from the levocetirizine group continued to get urticarial wheals. The addition of a prednisolone short course improves the symptomatic and clinical response of acute urticaria to antihistamines. Patients with steroids improved more quickly and completely without major adverse effects.
About this article
Cite this article
Godse, K. The role of prednisolone in acute urticaria management. Clin Transl Allergy 5, O8 (2015). https://doi.org/10.1186/2045-7022-5-S1-O8
- Public Health
- Adverse Effect
- Clinical Trial